Collaborations - Additional Information (Details) - USD ($) $ in Thousands			3 Months Ended	12 Months Ended
	Jul. 07, 2020	May 09, 2019	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unsatisfied performance obligation				$ 51,400
Revenue Recognized				55,000
Cost reimbursement payment received				8,800	$ 13,800
Unbilled accounts receivable			$ 3,800	900	3,800
Deferred revenue				$ 3,600
Remaining research term of collaboration				6 months
Private placement, net of issuance costs				$ 200	200	$ 174
Revenue recognized				47,072	78,592	46,826
Research and development				240,248	189,081	164,248
Milestone 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized recorded in deferred revenue					40,300
Deferred revenue			14,700		14,700
Unconstrained consideration			55,000		55,000
Collaboration Target 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestones Revenue Recognized				19,400
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 150,000
Collaboration agreement transaction price	150,000
Revenue recognized recorded in deferred revenue				47,100	70,200	36,000
Unsatisfied performance obligation			54,700	13,600	54,700
Revenue recognized					41,500
Sanofi Agreement | Milestone 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestones Revenue Recognized			40,000
Sanofi Agreement | Milestone 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestones Revenue Recognized			$ 15,000
Sanofi Agreement | Collaboration Target 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price	120,000
Revenue recognized recorded in deferred revenue					67,700	19,400
Sanofi Agreement | Collaboration Target 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price	30,000
Revenue recognized recorded in deferred revenue					2,500	16,600
Sanofi Agreement | Minimum | IRAK4 Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments	1,000,000
Commercial milestone payments	400,000
Sanofi Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments	1,480,000
Commercial milestone payments	$ 700,000
Vertex Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial research term of collaboration		4 years
Extended research term of collaboration		1 year
Revenue recognized				$ 0	$ 8,400	$ 10,800
Vertex Agreement | Series B-1 Convertible Preferred
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price		$ 55,900
Non refundable upfront payment received		$ 50,000
Issuance of shares, Shares		3,059,695
Preferred stock premium		$ 5,900
Vertex Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive payments including development, regulatory and commercial milestones		$ 170,000